Sanofi and IGM Biosciences team up to develop antibody agonists

Sanofi and IGM have announced the signing of a collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology and three immunology/inflammation targets.

Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies, which possess ten binding sites, compared to conventional IgG antibodies, which have only two target binding sites.

Under the terms of the collaboration, IGM will receive a $150m upfront payment, and, for each oncology target collaboration program, IGM will lead research and development activities. Following receipt of the first marketing approval for a product directed to an oncology target, Sanofi will lead all subsequent development and commercialization activities for that oncology target.

Original article by ?Pharma Times,